Advertising in the International Journal of Phonosurgery & Laryngology: A Media Planner's Guide to IJOPL Magazine Advertising in India

Most pharmaceutical marketers and medical device brands we speak with have never seriously considered journal advertisement India as a standalone media channel — and that, frankly, is a missed opportunity that costs them months of brand-building among precisely the specialists they are trying to reach. The International Journal of Phonosurgery & Laryngology sits in a rare category: a peer-reviewed journal with a hyper-defined readership of ENT surgeons, laryngologists, and voice pathologists across India and South Asia, which means every rupee spent on advertising reaches an audience that is clinically relevant, professionally engaged, and actively making prescribing and procurement decisions. We have spent years helping pharma brands, medical device companies, and healthcare-focused advertisers navigate the Indian medical publication landscape, and IJOPL consistently comes up as one of the most underutilised — and therefore underpriced — advertising channels available to brands targeting otolaryngology and phonosurgery specialists.

What Is the International Journal of Phonosurgery & Laryngology (IJOPL)?

There is something quietly impressive about a journal that has carved out such a specific niche in Indian medical publishing. The International Journal of Phonosurgery & Laryngology is the official publication of the Association of Phonosurgeons of India (APSI), which is the primary professional body for specialists working in phonosurgery, laryngology, voice surgery, and related disciplines across the subcontinent. Published by Jaypee Brothers Medical Publishers (P) Ltd — one of India's most respected and long-established medical publishing houses, headquartered in Daryaganj, New Delhi — the journal carries significant institutional credibility that general medical titles simply cannot replicate for this audience.

IJOPL carries the print ISSN 2230-7508 and the online ISSN 2231-3702, which are the identifiers you will find referenced across indexing databases and library catalogues including the National Library of India. The journal is a biannual journal publication, meaning it releases two issues per year, which is a publication frequency that actually works in an advertiser's favour — each issue has a longer shelf life on clinic desks and in hospital libraries than a monthly title would, and readership per issue tends to be meaningfully higher as a result. Digital preservation is handled through Portico, which signals to both the academic community and to advertisers that the journal is committed to long-term archival integrity; this matters because it speaks to the seriousness with which the editorial board and Jaypee Brothers approach the publication's permanence and reputation.

What a lot of people miss is the distinction between IJOPL and general otolaryngology titles. This is not a broad ENT journal covering every subspecialty under the sun; it is focused specifically on phonosurgery, laryngeal surgery, voice disorders, swallowing disorders, phonation research, thyroplasty, laryngoplasty, glottis and laryngeal pathology, and the clinical science of voice rehabilitation — which makes it extraordinarily targeted for brands whose products touch these specific therapeutic areas. At SmartAds, we always tell our clients that the narrower the journal's editorial focus, the higher the signal-to-noise ratio for your advertisement, and IJOPL is about as narrow and precise as Indian medical publishing gets in this subspecialty.

Why Should You Advertise in IJOPL's Print and Digital Editions?

The argument for advertising in a peer-reviewed journal like IJOPL is not about reach in the conventional sense — you are not going to match a television campaign's numbers, and nobody is pretending otherwise. The real argument is about quality of contact. When a practising ENT specialist or voice pathologist sits down with a copy of the International Journal of Phonosurgery & Laryngology, they are in a professional mindset, actively engaged with clinical content, which creates a receptivity to relevant advertising that no digital banner on a general news site can replicate. We have found, through campaigns we have managed for pharmaceutical clients, that the prescribing behaviour shift attributable to consistent journal advertisement India placements over two to three issue cycles is measurably stronger than equivalent spends on medical conference advertising alone.

On top of that, there is a brand-building dimension that takes time to appreciate fully. Indian otolaryngologists and surgical otolaryngology India specialists who see a brand consistently present in IJOPL across multiple issues begin to associate that brand with the subspecialty itself — it becomes part of the professional furniture, which is an outcome that no single-event sponsorship can manufacture. One pharmaceutical marketer we worked with — a mid-sized company launching a laryngeal topical product — was initially sceptical about committing to a biannual schedule, but after three consecutive issues their medical representatives reported that IJOPL recognition was being spontaneously mentioned by ENT specialists during detailing visits, which is an anecdotal but powerful signal of brand awareness penetration. The cost per reach in medical journal advertising, when calculated against the verified professional audience, works out to a figure that surprises most brand managers who are accustomed to thinking only in terms of mass media CPMs.

To be fair, IJOPL advertising is not for every brand. If your product has no meaningful connection to phonosurgery, laryngology, voice surgery, head and neck surgery, or otorhinolaryngology, then the audience alignment simply is not there and you would be better served by a broader ENT journal or a different channel entirely. But for pharmaceutical companies with products addressing voice disorders, laryngeal conditions, swallowing disorders, or related indications — and for medical device companies whose instruments are used in phonosurgery or laryngeal surgery — this journal represents targeted advertising at its most precise. The Association of Phonosurgeons of India's endorsement of the journal also carries weight with the readership, which means your advertisement appears in a context that the audience trusts and respects.

Who Is the Target Audience of IJOPL Magazine?

Understanding who actually reads the International Journal of Phonosurgery & Laryngology is the first question any serious media planner should ask before committing budget, and the answer is more nuanced than the journal's title might suggest. The primary readership consists of ENT surgeons and ENT specialists in India who have a subspecialty interest or active practice in phonosurgery and laryngology; these are typically senior consultants and associate professors at teaching hospitals, medical colleges, and tertiary care centres, which means they are both Key Opinion Leaders (KOLs) in their field and high-volume prescribers of the products relevant to their subspecialty.

Beyond surgeons, the readership extends to voice pathologists, speech-language pathologists with a clinical focus on voice rehabilitation, audiologists working in ENT departments, and postgraduate residents in otolaryngology who are building their clinical knowledge base — a segment that is particularly valuable for pharmaceutical marketers because these are the prescribers and influencers of tomorrow. The journal also reaches medical educators and researchers working in otorhinolaryngology, phonation science, and clinical research related to laryngeal pathology, which means that an advertisement placed in IJOPL is also seen by the people who write textbooks, conduct clinical trials, and present at national conferences. The Association of Otolaryngologists of India membership overlaps significantly with APSI membership, which broadens the effective reach beyond the strict phonosurgery subspecialty.

Geographically, the readership skews toward metro cities — New Delhi, Mumbai, Chennai, Bangalore, Hyderabad, and Kolkata — where the major teaching hospitals and ENT departments are concentrated, but a meaningful proportion of subscribers are practitioners in tier-2 cities where ENT services are expanding rapidly as healthcare infrastructure develops. What we tell our clients is that this geographic spread actually mirrors the distribution pattern of their own medical representative networks in most cases, which makes IJOPL advertising a useful complement to field force activity rather than a replacement for it. As a South Asia medical journal, IJOPL also reaches practitioners in Bangladesh, Sri Lanka, Nepal, and Pakistan, which is relevant for pharmaceutical companies with regional commercial operations.

What Types of Advertisements Does IJOPL Accept?

The range of advertising formats available through IJOPL is broader than most advertisers initially assume, and matching the right format to your campaign objective is something we spend a considerable amount of time on during media planning. For print advertisement placements, the journal offers the full suite of standard medical journal positions: the journal back cover advertisement (outside back cover), which commands the highest visibility and the strongest recall among print positions; the inside front cover ad, which is the first advertising surface a reader encounters when they open the journal; and full-page, half-page, and quarter-page placements within the body of the journal, which vary in cost and impact depending on their proximity to editorial content.

Digital advertisement options are increasingly important for brands that want to extend their reach beyond the physical print run. IJOPL's digital edition is accessible through JaypeeDigital, Jaypee Brothers' proprietary online platform, which gives advertisers the opportunity to place banner advertisement units alongside the journal's online content — reaching readers who access the journal digitally rather than through a physical subscription. These online journal advertising placements can be structured as run-of-site banners, section-specific placements adjacent to relevant clinical content, or as part of the e-TOC alert advertising programme, which we will address in detail separately. The combination of print advertisement and digital advertisement placements in a single campaign package is something we routinely recommend because it captures both the habitual print reader and the increasingly common digital-first subscriber.

For brands with larger budgets and a more ambitious brand-building objective, sponsored supplement options represent a qualitatively different kind of advertising investment — one that goes beyond a display ad and positions your brand as a contributor to clinical education within the specialty. Medical device advertising in particular benefits from this format because device companies often have complex products that require more than a single page to communicate effectively to a surgical audience. The journal also accepts journal reprint advertising, where a specific research article of relevance to your brand's therapeutic area can be reprinted with your company's branding for distribution at conferences or through medical representative channels, which is a format that blends advertising with clinical credibility in a way that pure display advertising cannot achieve.

How Do You Book an Advertisement in the International Journal of Phonosurgery & Laryngology?

The booking process for IJOPL advertising runs through Jaypee Brothers Medical Publishers (P) Ltd, and the primary advertisement contact is Mr. Sanjeev Kumar, whose details are available through the publisher's office in Daryaganj, New Delhi. For advertisers who are unfamiliar with the medical publishing ecosystem — which includes many brand managers who come from FMCG or consumer backgrounds — the process is more relationship-driven and less automated than booking a digital banner through a programmatic platform, which is actually an advantage because it allows for negotiation, customisation, and direct conversation about placement preferences and scheduling.

What we have found, through managing journal advertisement India bookings across multiple medical publications, is that early engagement with the publisher is essential — particularly for a biannual journal publication where there are only two issues per year and advertising inventory is genuinely limited. Brands that approach the booking process three to four months before the desired issue date have significantly more flexibility in terms of position selection and creative specifications than those who come in six weeks before publication. The advertising deadline calendar for IJOPL is tied to the editorial schedule, and missing the material submission deadline — even by a few days — typically means waiting for the next issue, which in a biannual publication means a six-month delay. This is one of the most common and avoidable mistakes we see pharmaceutical marketers make when they are managing journal placements without experienced media support.

At SmartAds, we manage the end-to-end IJOPL advertising booking process for our clients — from initial rate negotiation and position selection through to creative specification compliance and material submission — which removes the administrative burden from brand teams and ensures that deadlines are never missed. Our experience with Jaypee Brothers across multiple journals and multiple years means we understand the publisher's internal processes well enough to anticipate issues before they become problems. For brands that are advertising in the International Journal of Phonosurgery & Laryngology for the first time, having an experienced media partner handle the ad placement is genuinely worth the investment, not because the process is impossibly complicated, but because the cost of a missed issue in a biannual schedule is simply too high to risk.

What Are the Payment and Submission Guidelines for IJOPL Advertisers?

Payment terms for IJOPL advertising, like most Indian medical journal advertising, are typically structured on a per-issue basis with advance payment required before material submission is accepted. The publisher, Jaypee Brothers Medical Publishers (P) Ltd, operates on standard trade terms that are negotiable for multi-issue commitments — and in our experience, committing to both issues of a given volume year almost always unlocks better positioning and occasionally better rates than booking single issues independently. This is a straightforward piece of commercial logic that the advertising media plan for any serious journal campaign should account for from the outset.

For print advertisement submissions, the technical specifications that IJOPL requires are broadly consistent with Indian medical journal industry standards: full-page ads are typically sized to the journal's trim dimensions, artwork should be submitted at a minimum of 300 DPI in CMYK colour mode, and accepted file formats generally include high-resolution PDF, TIFF, or EPS files. It is worth noting that the editorial board advertisement policy at IJOPL, as with all reputable peer-reviewed journals, maintains a clear separation between editorial content and advertising content — which means that no advertisement, regardless of its size or the advertiser's relationship with the publisher, will be placed in a way that could be construed as editorial endorsement. This is not a limitation; it is actually a feature, because it protects the journal's credibility and, by extension, the credibility of every brand that appears within its pages.

For pharmaceutical advertising specifically, compliance with Central Drugs Standard Control Organisation (CDSCO) guidelines is non-negotiable, and the editorial board advertisement policy at IJOPL reflects this. Prescription drug advertisements must carry the mandatory scheduling information, the prescribing summary, and any required warnings as specified under Indian pharmaceutical marketing regulations. We always recommend that our pharmaceutical clients have their regulatory affairs team review advertisement materials before submission, and we build this review timeline into the overall booking schedule so that it does not compress the creative production window. Advertisers who submit non-compliant materials risk rejection, which in a biannual journal means a six-month setback — a risk that is entirely avoidable with proper planning.

How Does IJOPL's E-TOC Alert Advertising Work?

The e-TOC alert — the electronic table of contents notification that is sent to subscribers when a new issue of the International Journal of Phonosurgery & Laryngology is published — represents one of the most targeted and cost-effective digital touchpoints available to advertisers in this space, and it is consistently underestimated by brands that have not worked with journal advertising before. When a new issue is released, every subscriber who has opted into e-TOC alerts receives an email notification containing the issue's table of contents, which is the moment of highest engagement in the journal's digital lifecycle; the subscriber is actively interested in the new content, which means the e-TOC alert advertising placement benefits from a level of attention that a standard banner advertisement on a general medical portal simply cannot command.

Table of contents sponsorship within the e-TOC alert typically takes the form of a banner advertisement or a branded header/footer placement within the email itself, which reaches the journal's entire active digital subscriber base in a single send. The open rates for e-TOC alert emails from medical journals are, in our experience, substantially higher than general healthcare email marketing — somewhere in the range of 35 to 50 percent among active subscribers, which compares very favourably to the industry average for pharmaceutical email communications. This is not a surprising finding when you consider that the recipient has actively subscribed to receive this notification and is expecting clinical content, which creates a fundamentally different engagement context than unsolicited email marketing.

On top of the e-TOC alert, JaypeeDigital's online platform offers banner advertisement placements on the journal's digital homepage and article pages, which function as online journal advertising in the more conventional sense. These placements are served to readers who access IJOPL content digitally — a segment that has grown significantly as open access journal content has become more widely available and as younger ENT specialists increasingly prefer digital reading formats. We have found that combining an e-TOC alert advertising placement with a concurrent digital banner on the journal platform creates a frequency effect that meaningfully improves brand recall compared to either placement in isolation.

Can You Sponsor a Supplement in IJOPL?

Sponsored supplements represent the most immersive and brand-building format available in IJOPL advertising, and they are particularly well-suited to pharmaceutical companies and medical device companies that have a complex clinical story to tell — one that requires more space and editorial depth than a display advertisement can provide. A sponsored supplement is a separately published section of the journal, produced in collaboration with the journal's editorial team, which contains clinical content — typically review articles, case series, expert opinion pieces, or CME-accredited educational material — that is relevant to the sponsor's therapeutic area. The supplement carries the sponsor's branding and is distributed alongside the main journal issue, which means it reaches the same verified readership of ENT specialists, laryngologists, and voice pathologists.

The distinction between a sponsored supplement and an advertisement is important to understand clearly. A sponsored supplement is not an advertisement in the traditional sense; it is funded clinical content, which means the sponsor pays for production and distribution but does not control the editorial content — the journal's editorial board maintains independence over what is published. This distinction is what gives the format its credibility with the readership, and it is also why CDSCO compliance considerations apply differently to supplement content than to display advertising. For brands that are launching a new product in the phonosurgery or laryngology space, a sponsored supplement timed to coincide with a major APSI conference can be extraordinarily effective at establishing clinical credibility with the specialist audience.

We worked with a medical device company — a manufacturer of laryngoscopy equipment — that sponsored a supplement focused on advances in laryngeal surgery techniques; the supplement was distributed at the APSI annual conference and as an insert in the concurrent IJOPL issue, which gave it a combined reach that the brand's standalone conference presence could not have achieved independently. The feedback from their sales team in the months following publication was that the supplement had been retained by surgeons in a way that their standard conference brochures never were, which speaks to the fundamental difference between educational content and promotional material in terms of how healthcare professionals engage with it. Frankly speaking, this is where the real value of sponsored supplements lies — not in the immediate impression count, but in the durable presence they create in the professional environment.

How Does IJOPL Journal Advertising Compare to Other ENT Journals in India?

This is a question we get asked regularly, and it deserves a genuinely honest answer rather than a promotional one. The Indian Journal of Otolaryngology and Head & Neck Surgery (IJOHNS), published by Springer Nature in association with the Association of Otolaryngologists of India, is the most direct comparator to IJOPL in the Indian ENT publishing landscape — it is a quarterly publication with a broader editorial scope covering the full range of otolaryngology, head and neck surgery, and otorhinolaryngology subspecialties. IJOHNS has a larger subscriber base and a higher publication frequency, which means more advertising touchpoints per year and a wider reach across the ENT specialty as a whole; for brands targeting the broadest possible ENT audience, IJOHNS would typically be the primary vehicle.

IJOPL, by contrast, wins on specificity. If your brand is specifically relevant to phonosurgery, laryngology, voice disorders, voice surgery, swallowing disorders, or laryngeal surgery — which describes a meaningful subset of the ENT pharmaceutical and device market — then IJOPL's readership is more precisely aligned with your target prescriber profile than IJOHNS's broader ENT audience. The cost per reach in medical journal advertising, when calculated against the relevant specialist audience rather than the total readership, often favours IJOPL for these specific therapeutic categories. We have run the numbers for clients who were considering both journals simultaneously, and in several cases the IJOPL CPM against the phonosurgery-relevant prescriber segment worked out to be meaningfully lower than the equivalent IJOHNS figure, simply because the audience wastage was so much smaller.

The most effective advertising media plan for a brand with significant presence in the phonosurgery and laryngology space is, in our experience, to treat IJOPL and IJOHNS as complementary rather than competing placements — using IJOPL for deep subspecialty penetration and KOL engagement, and IJOHNS for broader ENT brand awareness. This kind of layered approach to medical journal advertising in India is something we build into integrated campaigns for pharmaceutical clients, and it consistently outperforms single-journal strategies in terms of both reach and frequency among the target prescriber population. The Dentsu e4m Report and FICCI-EY Media Report have both highlighted the resilience of print medical journal advertising in India even as digital channels grow, which validates the continued investment in this channel rather than treating it as a legacy medium.

What Makes Medical Journal Advertising Effective for Pharma Brands in India?

There is a persistent misconception in some marketing circles that print medical journal advertising is a declining channel — a relic of pre-digital pharmaceutical marketing that has been superseded by medical portals, social media for healthcare professionals, and programmatic digital advertising. Our experience shows that this view fundamentally misunderstands how Indian healthcare professionals actually consume information and how prescribing behaviour is formed. The TAM AdEx data on pharmaceutical advertising consistently shows that print — and specifically medical journal advertising — maintains a disproportionate share of pharmaceutical marketing spend relative to its apparent reach, precisely because the industry understands that reach alone is not the right metric for this channel.

What journal advertisement India placements actually buy is credibility by association. When a pharmaceutical brand or medical device company appears in a peer-reviewed journal like the International Journal of Phonosurgery & Laryngology, it is not just buying eyeballs; it is buying placement in a context that the reader associates with rigorous clinical science, professional authority, and peer-validated knowledge. This contextual credibility is something that no amount of digital banner advertising can manufacture, and it is why pharmaceutical advertising in medical journals continues to command premium rates relative to equivalent reach on digital platforms. The healthcare professional who sees your brand in IJOPL is receiving a subtle but powerful signal that your brand belongs in the same intellectual space as the clinical research they are reading — which is a brand awareness outcome that is genuinely difficult to achieve through any other channel.

At SmartAds, we have observed this effect most clearly in campaigns where journal advertising was combined with medical conference advertising and field force activity — a three-channel approach that creates multiple touchpoints with the same specialist audience across different contexts. One pharmaceutical client in the ENT space ran a coordinated campaign across IJOPL, a national otolaryngology conference, and their medical representative network over a twelve-month period; the brand awareness metrics among ENT specialists in India improved by a margin that their management team attributed primarily to the journal presence, because it was the only channel that reached specialists who were not accessible through the conference or the field force. Frankly speaking, the cost of that IJOPL advertising over the full year was a fraction of what the same brand spent on digital medical portal advertising — and the targeted advertising efficiency was substantially higher.

IJOPL Circulation, Reach, and Indexing: What Advertisers Need to Know

Circulation figures for Indian medical journals are not always published with the transparency that advertisers would prefer, and IJOPL is no exception to this pattern — which is why working with a media partner who has direct publisher relationships is genuinely useful. What we can say with confidence is that IJOPL's circulation is defined by the membership of the Association of Phonosurgeons of India, which represents the active phonosurgery and laryngology community in India, supplemented by institutional subscriptions from medical college libraries, hospital libraries, and individual ENT specialists with a subspecialty interest in phonosurgery. The bulk subscription model through APSI membership means that the journal reaches a verified professional audience rather than a self-selected general readership, which is a meaningful quality distinction for advertisers.

From an indexing perspective, IJOPL's presence in the National Library of India catalogue and its digital preservation through Portico are signals of the journal's standing in the medical publishing ecosystem. For advertisers, indexing matters because it correlates with the seriousness with which the readership engages with the journal — a well-indexed, institutionally recognised peer-reviewed journal is one that healthcare professionals treat as a credible professional resource rather than a trade publication. The online ISSN 2231-3702 facilitates digital access through JaypeeDigital and other platforms, which extends the journal's effective reach beyond the physical print circulation to include digital readers who access individual articles through online databases.

The geographic distribution of IJOPL readership within India reflects the distribution of ENT and phonosurgery practice — concentrated in metro cities and major medical education centres, but with meaningful representation in tier-2 cities as ENT services expand. For advertisers planning a journal advertisement India campaign, this geographic profile is worth mapping against their own sales territory data; in our experience, the overlap between IJOPL's readership geography and the target prescriber geography for most ENT-adjacent pharmaceutical products is strong enough that wastage is minimal. The South Asia medical journal reach — extending to Bangladesh, Sri Lanka, Nepal, and Pakistan — is an additional consideration for brands with regional commercial ambitions beyond India's borders.

Frequently Asked Questions About Advertising in IJOPL

Q: How do I place an advertisement in the International Journal of Phonosurgery & Laryngology?

The process begins with contacting Jaypee Brothers Medical Publishers (P) Ltd through their advertisement department — Mr. Sanjeev Kumar is the designated advertisement contact — at their office in Daryaganj, New Delhi. You will need to specify the issue you are targeting, the format and position you want (print, digital, or both), and provide your artwork or creative materials once the booking is confirmed. For brands working through SmartAds.in, we handle the entire booking and submission process on your behalf, which is particularly useful for first-time IJOPL advertisers who are unfamiliar with the publisher's internal processes and material specifications. The key practical point is to initiate the booking well in advance of the issue date — given the biannual publication frequency, missing a booking window means a six-month wait for the next opportunity.

Q: What are the advertising rates for IJOPL print and digital editions?

IJOPL does not publish a publicly available rate card, which is consistent with most Indian medical journals — rates are negotiated directly with the publisher and vary based on position, format, and whether you are booking a single issue or committing to multiple issues. What we can say from our experience managing medical journal advertising in India is that full-page print advertisement rates for specialist journals in this category typically fall somewhere in the range that makes the cost per verified specialist contact extremely competitive compared to equivalent digital medical portal placements. Inside front cover ad and journal back cover advertisement positions command a premium over run-of-journal placements, and digital banner advertisement rates are structured separately from print. We recommend contacting SmartAds.in for a customised rate benchmarking exercise before approaching the publisher directly, as having a reference point for negotiation is valuable.

Q: What types of advertisements does IJOPL accept — print, digital, or sponsored supplement?

IJOPL accepts the full range of medical journal advertising formats: print advertisement placements including full-page, half-page, and quarter-page positions as well as premium positions such as the inside front cover ad and journal back cover advertisement; digital advertisement placements including banner advertisement units on the JaypeeDigital platform and e-TOC alert advertising; and sponsored supplement productions for brands with a larger budget and a clinical education objective. Journal reprint advertising — where a specific article is reprinted with sponsor branding for conference or field force distribution — is also available through Jaypee Brothers. The editorial board advertisement policy maintains clear separation between editorial and advertising content across all formats, which protects both the journal's integrity and the advertiser's brand credibility.

Q: Who is the target readership of IJOPL, and how many subscribers does it have in India?

The primary readership consists of ENT surgeons and ENT specialists in India with a subspecialty focus in phonosurgery, laryngology, voice surgery, and related disciplines — essentially the membership of the Association of Phonosurgeons of India supplemented by institutional library subscribers and individual ENT specialists with a professional interest in the subspecialty. Voice pathologists, speech-language pathologists, and postgraduate ENT residents also form a meaningful segment of the readership. Precise subscriber count figures are not publicly disclosed by the publisher, but the readership is defined by the active phonosurgery and laryngology community in India, which is a small, highly specialised, and professionally influential group — exactly the audience that pharmaceutical marketers and medical device companies targeting this therapeutic area need to reach. The South Asia medical journal reach extends the audience to practitioners in neighbouring countries as well.

Q: How far in advance must I submit my advertisement material before publication?

In our experience managing journal advertisement India placements, material submission deadlines for IJOPL typically fall four to six weeks before the scheduled publication date, though the actual deadline varies by issue and should be confirmed with the publisher at the time of booking. Given that IJOPL is a biannual journal publication with only two issues per year, we strongly recommend initiating the booking process at least three to four months before your target issue date — this gives you time to confirm the position, produce and internally approve the creative materials, complete any regulatory review required for pharmaceutical advertising, and submit well ahead of the hard deadline. Missing the material deadline in a biannual journal is a significantly more costly mistake than in a monthly publication, which is why building adequate lead time into your advertising media plan is non-negotiable.

Q: Can pharmaceutical companies advertise prescription drugs in IJOPL?

Yes, pharmaceutical advertising for prescription drugs is accepted in IJOPL, subject to compliance with Central Drugs Standard Control Organisation (CDSCO) regulations governing pharmaceutical marketing in India. This means that prescription drug advertisements must include the mandatory scheduling classification, the abbreviated prescribing information, and any required safety warnings as specified under applicable regulations. The editorial board advertisement policy at IJOPL requires that all pharmaceutical advertising materials comply with applicable Indian pharmaceutical marketing regulations before they are accepted for publication; materials that do not meet these requirements will be rejected, which in a biannual publication schedule means a significant delay. We always recommend that our pharmaceutical clients have their regulatory affairs team review and approve all journal advertisement materials before submission, and we build this review step into our campaign timelines as a standard practice.

Q: What are the technical specifications for IJOPL print and digital ads?

For print advertisement submissions, artwork should be prepared at a minimum resolution of 300 DPI in CMYK colour mode, sized to the journal's trim dimensions (which should be confirmed with the publisher at the time of booking as they can vary). Accepted file formats for print typically include high-resolution PDF/X-1a, TIFF, or EPS files; RGB files are not suitable for print reproduction and will require conversion. For digital advertisement placements including banner advertisement units on JaypeeDigital and e-TOC alert advertising, standard web formats apply — JPEG, PNG, or animated GIF depending on the specific placement, with file size limits that the publisher will specify. We recommend requesting the full technical specification sheet from the publisher at the time of booking and sharing it with your design team before creative production begins, rather than retrofitting artwork to specifications after the fact.

Q: Is advertising in IJOPL effective for reaching ENT surgeons and laryngologists in India?

For brands whose products are specifically relevant to phonosurgery, laryngology, voice disorders, voice surgery, swallowing disorders, or laryngeal surgery, IJOPL advertising is among the most precisely targeted advertising options available in the Indian medical publication landscape. The readership is defined by the specialty itself — these are not general practitioners or broadly defined healthcare professionals; they are practising ENT specialists and laryngologists who are actively engaged with the clinical content that surrounds your advertisement. Our experience shows that consistent presence across multiple issues — which in a biannual journal means committing to a full year — produces meaningfully stronger brand awareness outcomes than single-issue placements, because the frequency effect requires more than one exposure to build the kind of professional familiarity that influences prescribing behaviour.

Q: How does IJOPL advertising compare to advertising in other ENT journals in India?

The most relevant comparator is the Indian Journal of Otolaryngology and Head & Neck Surgery (IJOHNS), which has a broader editorial scope, a higher publication frequency, and a larger subscriber base. For brands targeting the full ENT specialist audience, IJOHNS offers greater reach; for brands specifically targeting the phonosurgery and laryngology subspecialty, IJOPL offers superior audience alignment and lower effective wastage. The optimal approach for brands with significant commercial interest in this subspecialty is to use both journals in a coordinated advertising media plan — IJOPL for deep subspecialty penetration and IJOHNS for broader ENT brand awareness — rather than treating them as mutually exclusive options. Cost per reach in medical journal advertising, when calculated against the relevant prescriber segment rather than total circulation, often favours IJOPL for phonosurgery and laryngology-specific indications.

Q: What is the IJOPL e-TOC alert, and how can I sponsor it as an advertiser?

The e-TOC alert is the electronic notification sent to IJOPL's digital subscriber base when a new issue is published, containing the issue's table of contents and links to individual articles. Table of contents sponsorship within this email alert allows an advertiser to place a banner advertisement or branded element within the notification itself, reaching the journal's entire active digital subscriber base at the moment of highest engagement — when they are actively interested in the new issue's content. E-TOC alert advertising is booked through the same advertisement contact at Jaypee Brothers as print placements, and it can be combined with a concurrent print advertisement for a multi-channel campaign that reaches both print and digital readers. We recommend this combination particularly for product launches, where maximum coverage of the specialist audience within a single issue cycle is the primary objective.

Q: Does IJOPL offer sponsored supplement or custom reprint advertising options?

Yes, both formats are available. Sponsored supplements are separately published clinical content sections funded by a sponsor but editorially independent, distributed alongside the main journal issue and reaching the same verified specialist readership. They are best suited to brands with a complex clinical story — particularly medical device companies and pharmaceutical companies launching new products in the phonosurgery or laryngology space — because they provide the space and editorial depth that a display advertisement cannot. Journal reprint advertising involves the reprinting of a specific published article with sponsor branding for distribution through conference or field force channels; this format is particularly effective when a recently published study in IJOPL is directly relevant to your brand's clinical positioning. Both formats require early engagement with the publisher and a longer lead time than standard display advertising.

**Q: What is the editorial policy on advertisement acceptance or rejection at IJOPL